Real-world Medicolegal Issues in Dermatology and Dermatopathology

Medicolegal exposure is a pervasive challenge in both dermatology and dermatopathology. Despite advancements in diagnostic and therapeutic technology, malpractice litigation continues to affect clinicians and laboratories. Errors can occur at multiple stages, from biopsy technique and clinical judgment to histopathologic interpretation and patient follow-up. This article seeks to examine the medicolegal landscape affecting dermatologists and dermatopathologists, identify recurring sources of litigation, and provide practical strategies to minimize legal risk while upholding high standards of care. The majority of malpractice cases in dermatology and dermatopathology do not stem from gross negligence but from miscommunication, documentation lapses, sampling errors, and system-level failures. Common issues include delayed melanoma diagnosis, failure to recognize aggressive nonmelanoma skin cancers, incomplete biopsies, mismanaged follow-up, and inadequate documentation of informed consent. Systemic pressures such as managed care, private equity ownership, and unrealistic patient expectations further amplify exposure risk. Complete elimination of malpractice risk is impossible. However, dermatologists and dermatopathologists who practice meticulous clinicopathologic correlation, document decision-making, communicate clearly, and maintain professional boundaries within corporate systems can significantly reduce exposure.